Therapeutic | Imgatuzumab |
Target | EGFR |
Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | GlycoMAb Technology |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | GLYCART Biotechnology, Roche |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Colorectal cancer, Head and neck cancer, Non-small cell lung cancer |
Notes |